Fidelity Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fidelity Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$5.15B	Buy	15,806,521 +496,661	+3%	+$162M	0.29%	41
2025 Q1	$4.13B	Buy	15,309,860 +1,823,957	+14%	+$493M	0.26%	53
2024 Q4	$3.17B	Sell	13,485,903 -1,186,369	-8%	-$279M	0.19%	78
2024 Q3	$4.04B	Buy	14,672,272 +2,508,234	+21%	+$690M	0.25%	56
2024 Q2	$2.96B	Buy	12,164,038 +2,196,042	+22%	+$534M	0.19%	79
2024 Q1	$1.49B	Sell	9,967,996 -344,360	-3%	-$51.5M	0.1%	169
2023 Q4	$1.97B	Sell	10,312,356 -969,050	-9%	-$185M	0.15%	107
2023 Q3	$2B	Sell	11,281,406 -1,211,094	-10%	-$214M	0.17%	90
2023 Q2	$2.37B	Sell	12,492,500 -678,335	-5%	-$129M	0.2%	84
2023 Q1	$2.64B	Sell	13,170,835 -341,248	-3%	-$68.4M	0.24%	70
2022 Q4	$3.21B	Buy	13,512,083 +562,325	+4%	+$134M	0.32%	54
2022 Q3	$2.59B	Sell	12,949,758 -1,374,991	-10%	-$275M	0.27%	62
2022 Q2	$2.09B	Sell	14,324,749 -1,720,567	-11%	-$251M	0.21%	82
2022 Q1	$2.62B	Sell	16,045,316 -1,894,704	-11%	-$309M	0.21%	77
2021 Q4	$3.04B	Buy	17,940,020 +113,092	+0.6%	+$19.2M	0.22%	64
2021 Q3	$3.37B	Buy	17,826,928 +195,199	+1%	+$36.9M	0.27%	57
2021 Q2	$2.99B	Buy	17,631,729 +81,828	+0.5%	+$13.9M	0.23%	66
2021 Q1	$2.48B	Buy	17,549,901 +1,457,954	+9%	+$206M	0.21%	80
2020 Q4	$2.09B	Sell	16,091,947 -376,981	-2%	-$49M	0.19%	93
2020 Q3	$2.4B	Sell	16,468,928 -605,703	-4%	-$88.2M	0.24%	68
2020 Q2	$2.53B	Buy	17,074,631 +269,322	+2%	+$39.9M	0.28%	52
2020 Q1	$1.83B	Buy	16,805,309 +84,934	+0.5%	+$9.25M	0.25%	75
2019 Q4	$1.93B	Buy	16,720,375 +39,228	+0.2%	+$4.52M	0.21%	86
2019 Q3	$1.34B	Buy	16,681,147 +700,631	+4%	+$56.3M	0.16%	122
2019 Q2	$1.16B	Buy	15,980,516 +34,850	+0.2%	+$2.53M	0.14%	139
2019 Q1	$1.49B	Buy	15,945,666 +791,113	+5%	+$73.9M	0.18%	107
2018 Q4	$1.1B	Buy	15,154,553 +54,637	+0.4%	+$3.98M	0.15%	128
2018 Q3	$1.32B	Buy	15,099,916 +21,555	+0.1%	+$1.89M	0.15%	130
2018 Q2	$1.49B	Buy	15,078,361 +52,653	+0.4%	+$5.19M	0.17%	104
2018 Q1	$1.79B	Buy	15,025,708 +150,087	+1%	+$17.9M	0.21%	95
2017 Q4	$1.89B	Buy	14,875,621 +1,115,616	+8%	+$142M	0.22%	83
2017 Q3	$1.62B	Buy	13,760,005 +36,852	+0.3%	+$4.33M	0.2%	103
2017 Q2	$1.09B	Buy	13,723,153 +815,270	+6%	+$65M	0.14%	154
2017 Q1	$662M	Buy	12,907,883 +35,803	+0.3%	+$1.83M	0.08%	249
2016 Q4	$482M	Buy	12,872,080 +13,385	+0.1%	+$501K	0.06%	330
2016 Q3	$872M	Buy	12,858,695 +24,615	+0.2%	+$1.67M	0.12%	188
2016 Q2	$712M	Buy	12,834,080 +30,785	+0.2%	+$1.71M	0.1%	216
2016 Q1	$804M	Buy	12,803,295 +92,939	+0.7%	+$5.83M	0.11%	187
2015 Q4	$1.2B	Buy	12,710,356 +18,087	+0.1%	+$1.7M	0.16%	128
2015 Q3	$1.02B	Buy	12,692,269 +49,865	+0.4%	+$4.01M	0.15%	145
2015 Q2	$1.52B	Buy	12,642,404 +78,383	+0.6%	+$9.4M	0.19%	105
2015 Q1	$1.31B	Buy	12,564,021 +1,024,358	+9%	+$107M	0.17%	138
2014 Q4	$1.12B	Buy	11,539,663 +86,441	+0.8%	+$8.38M	0.15%	149
2014 Q3	$894M	Buy	11,453,222 +120,214	+1%	+$9.39M	0.12%	183
2014 Q2	$716M	Buy	11,333,008 +1,745,486	+18%	+$110M	0.1%	223
2014 Q1	$644M	Buy	9,587,522 +74,711	+0.8%	+$5.02M	0.09%	249
2013 Q4	$612M	Buy	9,512,811 +70,011	+0.7%	+$4.5M	0.09%	257
2013 Q3	$604M	Buy	9,442,800 +117,145	+1%	+$7.5M	0.09%	256
2013 Q2	$289M	Buy	+9,325,655	New	+$289M	0.05%	435